These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 16042740)

  • 1. Efficacy of tolterodine in children with overactive bladder.
    Koç B; Canpolat N; Adaletli İ; Sever L; Emir H; Çalışkan S
    Turk Pediatri Ars; 2020; 55(3):284-289. PubMed ID: 33061757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of bladder bowel dysfunction in children with urinary tract infections: a position statement from the International Children's Continence Society.
    Yang S; Chua ME; Bauer S; Wright A; Brandström P; Hoebeke P; Rittig S; De Gennaro M; Jackson E; Fonseca E; Nieuwhof-Leppink A; Austin P
    Pediatr Nephrol; 2018 Dec; 33(12):2207-2219. PubMed ID: 28975420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled trial of polyethylene glycol (MiraLAX®) for urinary urge symptoms.
    Bush NC; Shah A; Barber T; Yang M; Bernstein I; Snodgrass W
    J Pediatr Urol; 2013 Oct; 9(5):597-604. PubMed ID: 23127806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of lower urinary tract symptoms in school-age children.
    Vaz GT; Vasconcelos MM; Oliveira EA; Ferreira AL; Magalhães PG; Silva FM; Lima EM
    Pediatr Nephrol; 2012 Apr; 27(4):597-603. PubMed ID: 21969094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptom score for lower urinary tract dysfunction in pediatric urology.
    Wallis MC; Khoury AE
    Curr Urol Rep; 2006 Mar; 7(2):136-42. PubMed ID: 16526999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined anticholinergic treatment and behavioral modification as a first line treatment for nonneurogenic and nonanatomical voiding dysfunction in children: a randomized controlled trial.
    Ayan S; Topsakal K; Gokce G; Gultekin EY
    J Urol; 2007 Jun; 177(6):2325-8; discussion 2328-9. PubMed ID: 17509350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
    Babu R
    Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tolterodine in children with dysfunctional voiding: an initial report.
    Munding M; Wessells H; Thornberry B; Riden D
    J Urol; 2001 Mar; 165(3):926-8. PubMed ID: 11176516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children.
    Ayan S; Kaya K; Topsakal K; Kilicarslan H; Gokce G; Gultekin Y
    BJU Int; 2005 Aug; 96(3):411-4. PubMed ID: 16042740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine for treatment of overactive bladder.
    Kanofsky JA; Nitti VW
    Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.